PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
24.63%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
26.14%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
26.14%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
-26.20%
EBITDA decline while TRVN shows 47.36% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while TRVN shows 50.46% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-26.43%
Pre-tax income decline while TRVN shows 47.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Net income decline while TRVN shows 51.82% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while TRVN shows 56.59% growth. Joel Greenblatt would examine position.
-26.52%
Diluted EPS decline while TRVN shows 56.59% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x TRVN's 11.17%. David Dodd would verify capital allocation.
0.09%
Diluted share reduction exceeding 1.5x TRVN's 11.17%. David Dodd would verify capital allocation.